PBYI

PBYI

Last Updated:

Q3'20

Puma Biotechnology

At Puma Biotechnology, our focus is on bringing innovative therapies to patients to enhance cancer care.

We are thankful to be part of the HER2+ breast cancer community and are passionate about evaluating options that may benefit patients across the breast cancer therapy spectrum.

Cash

$109M

Burn Rate (Qtr)

-$31.5M

Pipeline Information

Click drug data to see upcoming trial info and prior data

Drug | Disease

Stage | Exp Date

Prior Data

NERLYNX

Metastatic HER2-positive breast cancer

Quarterly Sales (Approved)

February 19, 2021 (Est)

NERLYNX

HER2-positive breast cancer

Quarterly Sales (Approved)

February 19, 2021 (Est)

Trastuzumab Emtansine (T-DM1) With Neratinib

Metastatic HER2-Positive Breast Cancer

Phase 2 (Data)

Neratinib

Diarrhea in Patients with Early-Stage HER2+ Breast Cancer

Phase 2 (Data)

Q4 2020

Neratinib (HKI-272)

Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer and Brain Metastases

Phase 2 (Data)

H1 2021

Neratinib

Bile duct cancer patients with HER2 mutations

Phase 2 (Data)

H1 2021

Neratinib

Metastatic Cervical Cancers

Phase 2 (Pre-NDA meeting with the FDA)

H1 2021

Neratinib

Metastatic Non-Small Cell Lung Cancer

Phase 2

H1 2021

Recent Posts

See What The Community Is Saying - Click To See Full Post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon